Anixa Biosciences, Inc. ANIX
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.61% | -10.93% | -8.55% | -10.83% | -8.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.44% | -18.78% | -18.94% | -15.40% | -12.62% |
| Operating Income | 8.44% | 18.78% | 18.94% | 15.40% | 12.62% |
| Income Before Tax | 6.69% | 17.39% | 17.60% | 13.15% | 10.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.69% | 17.39% | 17.60% | 13.15% | 10.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -17.31% | -25.83% | -33.33% | -29.86% | -28.28% |
| Net Income | 6.59% | 17.31% | 17.42% | 12.96% | 10.08% |
| EBIT | 8.44% | 18.78% | 18.94% | 15.40% | 12.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 10.01% | 19.59% | 19.02% | 14.45% | 11.78% |
| Normalized Basic EPS | 9.99% | 19.57% | 18.92% | 14.32% | 11.67% |
| EPS Diluted | 10.01% | 19.59% | 19.02% | 14.45% | 11.78% |
| Normalized Diluted EPS | 9.99% | 19.57% | 18.92% | 14.32% | 11.67% |
| Average Basic Shares Outstanding | 3.79% | 2.81% | 1.96% | 1.74% | 2.01% |
| Average Diluted Shares Outstanding | 3.79% | 2.81% | 1.96% | 1.74% | 2.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |